Meyer Handelman Co. Sells 50,802 Shares of Pfizer Inc. $PFE

Meyer Handelman Co. cut its stake in Pfizer Inc. (NYSE:PFE) by 4.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,186,815 shares of the biopharmaceutical company’s stock after selling 50,802 shares during the period. Meyer Handelman Co.’s holdings in Pfizer were worth $29,552,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in PFE. Westmount Partners LLC lifted its holdings in Pfizer by 17.9% during the 4th quarter. Westmount Partners LLC now owns 10,402 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 1,576 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its stake in Pfizer by 15.1% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 171,142 shares of the biopharmaceutical company’s stock worth $4,261,000 after acquiring an additional 22,405 shares in the last quarter. Shrier Wealth Management LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $1,123,000. Foster & Motley Inc. increased its position in shares of Pfizer by 10.5% during the fourth quarter. Foster & Motley Inc. now owns 154,753 shares of the biopharmaceutical company’s stock worth $3,853,000 after acquiring an additional 14,670 shares during the period. Finally, Silver Oak Securities Incorporated raised its stake in shares of Pfizer by 32.8% during the fourth quarter. Silver Oak Securities Incorporated now owns 20,045 shares of the biopharmaceutical company’s stock valued at $501,000 after acquiring an additional 4,948 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

Pfizer Stock Performance

Shares of PFE stock opened at $28.08 on Wednesday. The firm has a market cap of $159.67 billion, a price-to-earnings ratio of 20.65 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.31. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average is $26.94 and its 200 day moving average is $25.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. UBS Group assumed coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective on the stock. Bank of America decreased their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Guggenheim raised their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.